Clinical Advances in Pituitary Diseases - Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing's Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
Mônica Gadelha, MD, PhD
Universidade Federal do Rio de Janeiro, Brazil
Clinical Advances in Pituitary Diseases - Metyrapone Treatment in Endogenous Cushing’s Syndrome: Results at Week 12 From PROMPT, a Prospective International Multicenter, Open-Label, Phase III/IV Study
Lynnette K Nieman, MD
National Institute of Diabetes and Digestive and Kidney Diseases, NIH, MD, United States
Clinical Advances in Pituitary Diseases - Chair
Shlomo Melmed, MB ChB
Cedars Sinai Medical Center, CA, United States
Clinical Advances in Pituitary Diseases - GLP1 Receptor Agonists Reduce Fluid Intake in Primary Polydipsia
Bettina Felicitas Winzeler, MD
University of Basel, Switzerland
Clinical Advances in Pituitary Diseases - One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
Susan Leanne Samson, MD,PhD
Baylor College of Medicine, TX, United States
